COVID Vaccines Development/Procurement/Distribution/Policy – Russia, China

Milestones :: Perspectives :: Research


COVID Vaccines Development/Procurement/Distribution/Policy – Russia, China



Sputnik V – “the first registered COVID-19 vaccine” [to 19 Dec 2020]
Press Releases
The Sputnik V vaccine’s efficacy is confirmed at 91.4% based on data analysis of the final control point of clinical trials
Press release, 14.12.2020
:: The efficacy of the Sputnik V vaccine is 91.4%, based on the final control point analysis of data obtained 21 days after administering the first dose…
:: The research data will be published by the Gamaleya Center team in one of the leading international peer-reviewed medical journals….

The number of Russians ready to be vaccinated against coronavirus has reached 42%, a FOM poll shows
Press release, 14.12.2020
A vaccine produced in Russia is the most trusted with 66% of those surveyed preferring it




National Medical Products Administration [to 19 Dec 2020]
China prepares for mass production of COVID-19 vaccines: official
Xinhua | Updated: 2020-12-17
BEIJING — China’s COVID-19 vaccine development has entered the “final sprint,” with the country preparing for the mass production of COVID-19 vaccines, according to an official from the National Health Commission (NHC).
The evaluation of a vaccine requires a number of comprehensive indicators, of which safety, effectiveness, accessibility and affordability are the most important, said Zheng Zhongwei, an official from the NHC.
China has adopted five technological approaches in developing COVID-19 vaccines, with 15 vaccines entering clinical trials, of which five are undergoing phase-3 clinical trials.
China is scientifically and rigorously promoting phase-3 clinical trials of COVID-19 vaccines and conducting review and approval in strict accordance with laws, regulations and internationally recognized technical standards to ensure the vaccines are safe, effective and can stand the test of time, according to Zheng.
The five vaccines in phase-3 clinical trials include two inactivated vaccines developed by the China National Biotec Group affiliated to Sinopharm, an inactivated vaccine developed by Sinovac Biotech, an adenovirus vector vaccine developed by the Academy of Military Sciences and CanSino Biologics Inc., and a recombinant sub-unit vaccine jointly developed by Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. and the Institute of Microbiology under the Chinese Academy of Sciences.
As the epidemic has been effectively controlled in China, the country no longer has the conditions to carry out phase-3 clinical trials. These are being carried out overseas, which also brings some difficulties and challenges, according to Zheng.
China granted emergency use of COVID-19 vaccines in June.

China honors its commitments on COVID-19 vaccine
BEIJING — China is fulfilling its commitments with concrete actions to ensure the accessibility and affordability of COVID-19 vaccines in developing countries, a Foreign Ministry spokesperson said on Dec 15.
Chinese vaccine companies are sparing no effort to advance their vaccine research and development, and several vaccines have entered phase-three clinical trials, spokesperson Wang Wenbin said at a daily news briefing in response to a relevant question.
The Chinese government has been actively supporting cooperation between Chinese companies and other countries in vaccine research and development, he said, adding that China is in close communication and cooperation with the World Health Organization and the Global Alliance for Vaccines and Immunization.
The Chinese government will continue to work together with the international community to help ensure all countries will have equal access to safe and effective vaccines. For underdeveloped or some developing countries, China will help with their vaccine accessibility and affordability through such means as aid, Wang said.
When answering a question on the transparency in authorizing emergency use of the COVID-19 vaccine, the spokesperson said China always attaches great importance to vaccine safety and efficacy.
“Chinese vaccine companies advance research and development in strict accordance with science and regulation requirements and engage in international cooperation in strict compliance with international standards and relevant laws and regulations,” said Wang.
He said that some countries had already approved China’s vaccine for use, which had proved the safety and efficacy of China’s vaccine.
“We stand ready to work with other countries to advance vaccine research and development cooperation and contribute to vaccine accessibility and affordability in the world, in particular developing countries so the world can vanquish the pandemic at an early date,” Wang added.